Carfilzomib Works Well As Salvage Therapy; Momentum Builds For Frontline Role
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Onyx Pharmaceuticals, Inc. reported positive trial results from a Phase IIb study showing its oral proteasome inhibitor carfilzomib works well as a single salvage treatment for multiple myeloma, lending some support to the company’s plans to seek accelerated approval in this area of high unmet need.
You may also be interested in...
Carfilzomib On Track For End-of-Year Submission After Surprising Top-line Phase II Results
Onyx's next-generation proteasome inhibitor shows a 24% response rate, 7.4 month durable response as a salvage therapy in multiple myeloma.
Market Snapshot: Multiple Myeloma Drugs Promise To Live Up To Hype
Spurred by the introduction of new and highly effective drugs that have vastly improved survival rates, the fast-moving myeloma market is becoming a very attractive sector in oncology
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.